Acceptability of intrauterine levonorgestrel delivery system (Mirena® 52mg) after estrogen-progesterone oral contraception: Results of a prospective multicentric study of 211 patients aged 25-35 years;Acceptabilité du système intra-utérin au lévonorgestrel Mirena® 52 mg après contraception orale œstroprogestative: Résultats à 1 an d'une étude prospective multicentrique sur 211 patientes de 25 à 35 ans

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 35, Issue 8, 2006, Pages 778-784

  Collinet, P ^a   Nayama, M ^a   Cosson, M ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Levenorgestrel; Mirena ; Oral contraception

Indexed keywords

ESTROGEN; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; PROGESTERONE;

ABDOMINAL PAIN; ACNE; ADULT; AMENORRHEA; ARTICLE; BLEEDING; CONTROLLED STUDY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DYSMENORRHEA; DYSPAREUNIA; FEMALE; HUMAN; INFECTION; INTRAUTERINE CONTRACEPTIVE DEVICE; LEUKOCYTOSIS; MALAISE; MASTALGIA; MENSTRUAL CYCLE; METRORRHAGIA; MIGRAINE; ORAL CONTRACEPTION; OUTCOME ASSESSMENT; OVARY DISEASE; PAIN; PATIENT COMPLIANCE; PATIENT SATISFACTION; SPOTTING; TREATMENT DURATION;

EID: 33845526995     PISSN: 03682315     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0368-2315(06)76479-1     Document Type: Article

References (19)

1. Silverberg SG. Endometrial morphology during long term use of levonorgestrel-releasing intrauterine devices. Int J Gynecol Pathol 1986; 5: 235-41.
2. Jonnson B. Effects of various IUDs on the composition of cevical mucus. Contraception 1991; 43: 447-58.
3. Luukkainen T. Levonorgestrel releasing IUD as a method of contraception with therapeutic properties. Contraception 1995; 52: 269-76.
4. Andersson K. Levonorgestrel-releasing and copper releasing (NovaT) IUDs during five years of use: a randomized comparative trial. Contraception 1994; 49: 56-72.
5. Sivin I. Health during prolonged use of levonorgestrel 20μg/d and the copper Tcu380Ag intrauterine contraceptive devices: a multicenter study. Fertility Steril 1994; 61: 70-7.
6. Lahteenmaki P, Rauramo I, Backman T. The levonorgestrel intrauterine system in contraception. Steroids 2000; 65: 693-7.
7. Suhonen S. Clinical performances of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: a comparative study. Contraception 2004; 69: 407-12.
8. Ronnerdag M Health effects of a long-term use of the intrauterine levonorgestrel-releasing system. Acta Obstet Gynecol Scand 1999; 78: 716-21.
9. Dubuisson JB, Mugnier E. Acceptability of the levonorgestrel-releasing intrauterine system after discontinuation of previous contraception: results of a French clinical study in women aged 35 to 45 years. Contraception 2002; 66: 121-8.
10. RCP Mirena.
11. Trussell J. Contraceptive failure in the United States. Contraception 2004; 70: 89-96.
12. Zalel Y, Gamzu R, Shulman A, Achiron R, Schiff G, Lidor A. The progestative effect of the levonorgestrel-releasing intrauterine system: when does it manifest? Contraception 2003; 67: 473-6.
13. Nilsson CG, Lahteenmaki P, Luukkainen T. Levonorgestrel plasma concentrations and hormone profiles after insertion and after one year of treatment with a levonorgestrel-IUD. Contraception 1980; 21: 225-33.
14. Funk S. Safety and efficacy of Implanon: a single rod implantable contraceptive containing etonogestrel. Contraception 2005; 71: 319-26.
15. Hague S, MacKenzie IZ, Bicknell R, Rees MC. In vivo angiogenesis and progestatgens. Human Reprod 2002; 17: 786-93.
16. Jondet M, Letellier B, Verdys MT. Endometrial vascularisationin levinorgestrel intra uterine device users;computerized microvessel measurement study. Contraception 2005; 71: 60-4.
17. Nascimento R, Bahamondes L, Hidalgo M, Perrotti M, Espejo-Arce X, Petta CA. Users' perspectives on bleeding patterns after two years of levonorgestrel-releasing intrauterine system use. Drugs R D 2002; 3: 387-91.
18. Rogovskaya S, Rivera R, Grimes DA, Chen PL, Pierre-Louis B, Prilepskaya V et al. Effect of a levonorgestrel intrauterine system on women with type 1 diabetes: a randomized trial. Obstet Gynecol 2005; 105: 811-5.
19. Backman T. Advance information improves user satisfaction with the levonorgestrel intra uterine system. Obstet Gynecol 2002; 99: 608-13.